Global and China Monoclonal Antibody Industry Report 2013 Analysis and 2017 Market Focus by Researchmoz.us - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
December 25, 2013 Newswires
Share
Share
Post
Email

Global and China Monoclonal Antibody Industry Report 2013 Analysis and 2017 Market Focus by Researchmoz.us

PR Web

Albany, NY (PRWEB) December 25, 2013

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period.

Browse Full Report With TOC at: http://www.researchmoz.us/global-and-china-monoclonal-antibody-industry-report-2013-2017-report.html

Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.

Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012).

The global monoclonal antibody industry is still dominated by European and American companies, especially, important monoclonal antibody products are mainly produced by Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson and other companies. In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche) stemmed from the above four companies. The global sales (including the sales of third parties) of these six monoclonal antibody agents totaled USD45 billion, accounting for 57.7% of the global.

Find More Reports from Research in China Publisher at: http://www.researchmoz.us/publisher/research-in-china-67.html

In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012.

However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year).

Related Reports:-

Global Bioinformatics Market 2014-2018

Global Bioinformatics market to grow at a CAGR of 26.15 percent over the period 2013-2018. One of the key factors contributing to this market growth is the decreasing cost of genetic sequencing. The Global Bioinformatics market has also been witnessing the increasing outsourcing of bioinformatics services. However, the complexity in using bioinformatics tools could pose a challenge to the growth of this market. The Global Bioinformatics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC region; it also covers the Global Bioinformatics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Browse Full Report with TOC at: http://www.researchmoz.us/global-bioinformatics-market-2014-2018-report.html
China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradually recognized internationally, China has grown into the largest heparin API producing and exporting country around the globe. Nevertheless, due to the stagnant demand in European and American markets in recent two years and the improved standards for heparin export, the export volume and value of heparin APIs in China both presented a decline trend during 2011-2012.
Browse Full Report wtih TOC at: http://www.researchmoz.us/china-heparin-industry-report-2013-2015-report.html

About Us:

ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.

For More Information Kindly Contact:
Mrs.Sheela AK Tel:+1-518-618-1030
Toll Free: 866-997-4948
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Email: sales(at)researchmoz(dot)us
Blog: http://researchmoz.blogspot.com/

Read the full story at http://www.prweb.com/releases/2013/12/prweb11446822.htm

Copyright:  (c) 2013 PRWEB.COM Newswire
Wordcount:  698

Advisor News

  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
  • Election results cloud retirement legislation outlook, experts say
  • Planning for the missing chapter
More Advisor News

Annuity News

  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
  • ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
  • Jackson Launches Direct-to-Consumer Annuity Offering
More Annuity News

Health/Employee Benefits News

  • Samantha Wildow: Mercy Health warns thousands of Medical Mutual of Ohio patients may go out-of-network in 2027
  • Reports Outline Managed Care Study Results from Harvard University (Inpatient-Only List Removals Shifted Procedures To The Outpatient Setting And Reduced Medicare Spending): Managed Care
  • Health and Humor: Picking a Medicare insurance plan is daunting
  • Obamacare is getting more expensive in Indiana
  • Hays City Commission to consider bids for health insurance, sports complex improvements
More Health/Employee Benefits News

Life Insurance News

  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • U-Haul Holding Company to Participate in Deutsche Bank Conference
  • NAIC task force to address LTC riders
  • Protective names Kurt Meyers Chief Legal Officer and Fernando Levy Chief Digital & AI Officer
  • Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.